These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34872507)

  • 1. Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
    Zhang J; Jiang H; Zhang J; Bao G; Zhang G; Wang H; Wang X
    BMC Cancer; 2021 Dec; 21(1):1301. PubMed ID: 34872507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study.
    Tseng LM; Chen FM; Chen ST; Cheng FT; Chao TY; Dai MS; Kao WY; Yeh MH; Chen DR; Liu LC; Wang HC; Chang HT; Wang BW; Yu JC; Chen SC; Liao GS; Hou MF
    Oncol Res Treat; 2024; 47(10):484-495. PubMed ID: 39033747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
    Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
    Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
    J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
    Khallaf SM; Roshdy J; Ibrahim A
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.
    Liu W; Chen W; Zhang X; Zhao P; Fan Z; Bi L; Wu D; Li S; Yang M; Fu T; Song D; Han B; Zhao G; Du Y; Shi A
    Sci Rep; 2021 Jan; 11(1):199. PubMed ID: 33420241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case-control study.
    Tsai JH; Li CL; Yeh DC; Hung CS; Hung CC; Lin CY; Kuo YL
    Breast Cancer Res Treat; 2023 May; 199(1):47-55. PubMed ID: 36869992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
    Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
    Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
    Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
    Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
    Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.
    Hong Y; Peng J; Chen Q; Zhou Q; Xu F; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Zhang D; Wang S; Yi W
    Ther Adv Med Oncol; 2024; 16():17588359241279695. PubMed ID: 39346118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
    Zhang M; Li L; Zhang S; Zhu W; Yang S; Di G; Ma X; Yang H
    Biomed Res Int; 2020; 2020():3208391. PubMed ID: 32461977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
    Yang H; Zhou L; Wang S; Cao Y; Tong F; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Guo J; Wang S; Peng Y
    Medicine (Baltimore); 2018 Oct; 97(40):e12690. PubMed ID: 30290661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
    Dong M; Luo L; Ying X; Lu X; Shen J; Jiang Z; Wang L
    Onco Targets Ther; 2018; 11():4247-4252. PubMed ID: 30087568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
    Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
    J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy Of Pegylated Liposomal Doxorubicin-based Neoadjuvant Chemotherapy In Breast Cancer: A Single Center Experience.
    Tsai IC; Hung CC
    Clin Invest Med; 2021 Mar; 44(1):E7-14. PubMed ID: 33743571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.